WO2004029031A3 - Therapeutic piperazine compounds - Google Patents

Therapeutic piperazine compounds Download PDF

Info

Publication number
WO2004029031A3
WO2004029031A3 PCT/US2003/030185 US0330185W WO2004029031A3 WO 2004029031 A3 WO2004029031 A3 WO 2004029031A3 US 0330185 W US0330185 W US 0330185W WO 2004029031 A3 WO2004029031 A3 WO 2004029031A3
Authority
WO
WIPO (PCT)
Prior art keywords
piperazine compounds
compound
therapeutic
animal
disclosed
Prior art date
Application number
PCT/US2003/030185
Other languages
French (fr)
Other versions
WO2004029031A2 (en
Inventor
Qun Sun
Xiaoming Zhou
Original Assignee
Euro Celtque S A
Qun Sun
Xiaoming Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200330815T priority Critical patent/SI1562936T1/en
Priority to MXPA05003302A priority patent/MXPA05003302A/en
Priority to JP2004539882A priority patent/JP4560610B2/en
Priority to DK03754883T priority patent/DK1562936T3/en
Priority to CA2500113A priority patent/CA2500113C/en
Priority to DE60312544T priority patent/DE60312544T2/en
Priority to NZ539205A priority patent/NZ539205A/en
Priority to EP03754883A priority patent/EP1562936B1/en
Application filed by Euro Celtque S A, Qun Sun, Xiaoming Zhou filed Critical Euro Celtque S A
Priority to BR0314699-5A priority patent/BR0314699A/en
Priority to AU2003272685A priority patent/AU2003272685A1/en
Publication of WO2004029031A2 publication Critical patent/WO2004029031A2/en
Publication of WO2004029031A3 publication Critical patent/WO2004029031A3/en
Priority to HK06102046A priority patent/HK1083216A1/en
Priority to CY20071100730T priority patent/CY1106634T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

A compound of formula: wherein Ar, Ar1, Ar2, R3-R6, R13, m, and t are disclosed herein, or a pharmaceutically acceptable salt thereof (a 'Hydroxyiminopiperazine Compound'); compositions comprising an effective amount of a Hydroxyiminopiperazine Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Hydroxyiminopiperazine Compound are disclosed.
PCT/US2003/030185 2002-09-24 2003-09-24 Therapeutic piperazine compounds WO2004029031A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
NZ539205A NZ539205A (en) 2002-09-24 2003-09-24 Therapeutic piperazine compounds
JP2004539882A JP4560610B2 (en) 2002-09-24 2003-09-24 Therapeutic piperazine compounds
DK03754883T DK1562936T3 (en) 2002-09-24 2003-09-24 Therapeutic piperazine compounds
CA2500113A CA2500113C (en) 2002-09-24 2003-09-24 Therapeutic piperazine compounds
DE60312544T DE60312544T2 (en) 2002-09-24 2003-09-24 THERAPEUTIC PIPERAZINE COMPOUNDS.
SI200330815T SI1562936T1 (en) 2002-09-24 2003-09-24 Therapeutic piperazine compounds
EP03754883A EP1562936B1 (en) 2002-09-24 2003-09-24 Therapeutic piperazine compounds
MXPA05003302A MXPA05003302A (en) 2002-09-24 2003-09-24 Therapeutic piperazine compounds.
BR0314699-5A BR0314699A (en) 2002-09-24 2003-09-24 Compound, composition and methods for treating pain and inhibiting vr1 function in a cell
AU2003272685A AU2003272685A1 (en) 2002-09-24 2003-09-24 Therapeutic piperazine compounds
HK06102046A HK1083216A1 (en) 2002-09-24 2006-02-16 Terapeutic piperazine compounds
CY20071100730T CY1106634T1 (en) 2002-09-24 2007-06-04 THERAPEUTIC DERIVATIVES OF PIPERAZINE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41284702P 2002-09-24 2002-09-24
US60/412,847 2002-09-24

Publications (2)

Publication Number Publication Date
WO2004029031A2 WO2004029031A2 (en) 2004-04-08
WO2004029031A3 true WO2004029031A3 (en) 2004-08-05

Family

ID=32043195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/030185 WO2004029031A2 (en) 2002-09-24 2003-09-24 Therapeutic piperazine compounds

Country Status (20)

Country Link
US (4) US7157462B2 (en)
EP (2) EP1810970B8 (en)
JP (1) JP4560610B2 (en)
KR (1) KR20050052514A (en)
CN (1) CN100393713C (en)
AT (2) ATE356817T1 (en)
AU (1) AU2003272685A1 (en)
BR (1) BR0314699A (en)
CA (1) CA2500113C (en)
CY (1) CY1106634T1 (en)
DE (2) DE60332562D1 (en)
DK (1) DK1562936T3 (en)
ES (1) ES2285170T3 (en)
HK (1) HK1083216A1 (en)
MX (1) MXPA05003302A (en)
NZ (1) NZ539205A (en)
PT (1) PT1562936E (en)
SI (1) SI1562936T1 (en)
WO (1) WO2004029031A2 (en)
ZA (1) ZA200502326B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100891887B1 (en) 2001-01-29 2009-04-03 시오노기세이야쿠가부시키가이샤 Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
US7157462B2 (en) * 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
PL1648878T3 (en) * 2003-07-24 2009-10-30 Euro Celtique Sa Piperidine compounds and pharmaceutical compositions containing them
SI1867644T1 (en) 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
ES2374017T3 (en) 2003-08-01 2012-02-13 Euro-Celtique S.A. USEFUL THERAPEUTIC AGENTS FOR THE TREATMENT OF PAIN.
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CN101212967A (en) 2005-05-10 2008-07-02 因塞特公司 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
JP5294874B2 (en) 2005-12-20 2013-09-18 インサイト・コーポレイション N-hydroxyamidino heterocycle as modulator of indoleamine 2,3-dioxygenase
US20070203140A1 (en) * 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
US7879870B2 (en) * 2006-04-19 2011-02-01 Smith Jill P Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
WO2008057300A2 (en) * 2006-10-27 2008-05-15 Redpoint Bio Corporation Trpvi antagonists and uses thereof
UY31050A1 (en) * 2007-04-27 2008-07-03 Shionogi & Co TRPV1 ANTAGONISTS AND USES OF THE SAME
US20090105348A1 (en) * 2007-10-18 2009-04-23 Harry Fisch Treatment of migraine headaches using antiestrogens
EP2238105B1 (en) 2008-01-28 2014-04-16 Amorepacific Corporation Novel compounds as vanilloid receptor antagonists
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
SI2824100T1 (en) 2008-07-08 2018-06-29 Incyte Holdings Corporation 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
EP2536283B8 (en) 2010-02-18 2015-11-04 vTv Therapeutics LLC Phenyl-heteroaryl derivatives and methods of use thereof
JP5876423B2 (en) 2010-06-22 2016-03-02 塩野義製薬株式会社 Compounds having TRPV1 inhibitory activity and uses thereof
US9156830B2 (en) 2011-05-17 2015-10-13 Shionogi & Co., Ltd. Heterocyclic compounds
TWI453205B (en) 2011-06-22 2014-09-21 Purdue Pharma Lp Trpv1 antagonists including dihydroxy substituent and uses thereof
SG11201603433UA (en) 2013-11-08 2016-05-30 Incyte Corp Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US11443441B2 (en) 2017-02-24 2022-09-13 Brainlab Ag Deep inspiration breath-hold setup using x-ray imaging
AU2022267044A1 (en) 2021-04-26 2023-11-30 Pathios Therapeutics Limited Compounds
DE102022104759A1 (en) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-crystal screening method, in particular for the production of co-crystals

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052001A1 (en) * 1999-03-03 2000-09-08 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439606A (en) 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
US4450272A (en) 1982-05-06 1984-05-22 American Cyanamid Company Antiatherosclerotic 1-piperazine-thicarboxamides
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3822792C2 (en) 1987-07-11 1997-11-27 Sandoz Ag New use of 5HT¶3¶ antagonists
US5198459A (en) 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5232934A (en) 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
DE4234295A1 (en) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carboxylic acid derivatives, medicaments containing these compounds and process for their preparation
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
GB9306578D0 (en) 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
GB9308725D0 (en) 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
US5461047A (en) 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
FR2722788B1 (en) 1994-07-20 1996-10-04 Pf Medicament NOVEL PIPERAZIDES DERIVED FROM ARYL PIPERAZINE, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5762925A (en) 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
CZ288002B6 (en) 1995-01-11 2001-03-14 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and pharmaceutical preparation exhibiting antitumor activity, in which the derivatives are comprised
AU713171B2 (en) 1996-06-29 1999-11-25 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
JP2003524574A (en) 1997-08-05 2003-08-19 ノボ ノルディスク アクティーゼルスカブ 2,5- and 3,5-disubstituted aniline derivatives, their preparation and use
US6423716B1 (en) 1998-03-31 2002-07-23 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
EP1122242B1 (en) 1998-09-22 2008-01-16 Astellas Pharma Inc. Cyanophenyl derivatives
US6109269A (en) 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion
EP1313477A4 (en) 2000-07-15 2004-03-03 Smithkline Beecham Corp Compounds and methods
US6723730B2 (en) * 2000-07-20 2004-04-20 Neurogen Corporation Capsaicin receptor ligands
KR100453078B1 (en) 2000-08-21 2004-10-15 주식회사 태평양 Novel thiourea compounds and the pharmaceutical compositions containing the same
DE60133743T2 (en) 2000-08-21 2009-07-02 Pacific Corp. NEW THIOUREA DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PE20030417A1 (en) 2001-09-13 2003-08-06 Smithkline Beecham Plc DERIVATIVES OF UREA AS ANTAGONISTS OF THE VAINILLOID RECEPTOR
RS63204A (en) 2002-01-17 2006-10-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
AU2003245773A1 (en) 2002-02-15 2003-09-04 Glaxo Group Limited Vanilloid receptor modulators
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2003247829A1 (en) * 2002-06-28 2004-01-19 Euro-Celtique, S.A. Therapeutic piperazine derivatives useful for treating pain
US7157462B2 (en) * 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
SI1867644T1 (en) * 2003-07-24 2009-10-31 Euro Celtique Sa Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
PL1648878T3 (en) * 2003-07-24 2009-10-30 Euro Celtique Sa Piperidine compounds and pharmaceutical compositions containing them
CA2551862A1 (en) * 2003-12-30 2005-07-21 Euro-Celtique S.A. Piperazines useful for treating pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052001A1 (en) * 1999-03-03 2000-09-08 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof

Also Published As

Publication number Publication date
US7737148B2 (en) 2010-06-15
JP2006508067A (en) 2006-03-09
CN1701071A (en) 2005-11-23
ZA200502326B (en) 2006-05-31
CA2500113C (en) 2011-07-12
EP1810970B1 (en) 2010-05-12
NZ539205A (en) 2007-05-31
EP1562936A2 (en) 2005-08-17
US20050059671A1 (en) 2005-03-17
CY1106634T1 (en) 2012-01-25
EP1562936B1 (en) 2007-03-14
HK1083216A1 (en) 2006-06-30
ATE356817T1 (en) 2007-04-15
EP1810970B8 (en) 2012-03-21
DE60312544T2 (en) 2007-12-13
ES2285170T3 (en) 2007-11-16
CN100393713C (en) 2008-06-11
DE60332562D1 (en) 2010-06-24
SI1562936T1 (en) 2007-08-31
KR20050052514A (en) 2005-06-02
US7855210B2 (en) 2010-12-21
PT1562936E (en) 2007-06-12
US7157462B2 (en) 2007-01-02
US20090042902A1 (en) 2009-02-12
DE60312544D1 (en) 2007-04-26
US20110082152A1 (en) 2011-04-07
ATE467627T1 (en) 2010-05-15
CA2500113A1 (en) 2004-04-08
JP4560610B2 (en) 2010-10-13
BR0314699A (en) 2005-08-09
US20070142360A1 (en) 2007-06-21
EP1810970A1 (en) 2007-07-25
MXPA05003302A (en) 2005-10-18
DK1562936T3 (en) 2007-07-16
WO2004029031A2 (en) 2004-04-08
AU2003272685A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
WO2004029031A3 (en) Therapeutic piperazine compounds
HK1091481A1 (en) Therapeutic agents useful for treating pain
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
WO2005056524A3 (en) Therapeutic agents useful for treating pain
HK1094191A1 (en) Phenyl-carboxamide compounds useful for treating pain
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
MXPA05013587A (en) Therapeutic agents useful for treating pain.
RU94044436A (en) Method of suppression of skin and vagina atrophy
RU94044454A (en) Inhibitor of autoimmune diseases
ATE366107T1 (en) USE OF SULFODEHYDROABIETIC ACID TO TREAT INFLAMMATORY BOWEL DISEASE
EA200601249A1 (en) PIPERASINS, SUITABLE FOR THE TREATMENT OF PAIN
GEP20043231B (en) Resorcinol Composition
WO2001007029A3 (en) Substituted guanidines and the use thereof
WO2005035500A3 (en) Therapeutic agents useful for treating pain
ECSP055804A (en) PHARMACEUTICAL COMPOSITION
AU2002211217A1 (en) Method of treating stroke
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005/02326

Country of ref document: ZA

Ref document number: 200502326

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003272685

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500585

Country of ref document: PH

Ref document number: 167604

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004539882

Country of ref document: JP

Ref document number: 2500113

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020057005096

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/003302

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 539205

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003754883

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 670/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003825297X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057005096

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003754883

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003754883

Country of ref document: EP